EU allows Roche’s Tarceva for pancreatic cancer

Categories: Uncategorized

The European Union approved Roche’s cancer drug Tarceva for use against pancreatic cancer, Roche said on Monday, in line with an earlier recommendation from EU authorities.

Roche said the approval was based on data from a phase III study, showing that treatment with Tarceva resulted in significant longer survival of patients, compared to those treated with chemotherapy alone.

Last month, the European Medicines Agency had decided to recommend Tarceva for use against pancreatic cancer after re-examining evidence, having earlier rejected the medicine as a treatment for advanced pancreatic cancer.

You Might Like:
  • High-dose chemo doesn’t improve survival in metastatic breast cancer
  • Comorbidity reduces benefits of androgen suppression in prostate cancer
  • Statins don’t appear to be linked with breast cancer risk
  • Soft-tissue sarcoma outcomes vary widely by race, ethnicity
  • Even small copay deters mammogram use: U.S. study
  • Effective prostate cancer screening requires digital rectal exam
  • Clinical trial access more limited for teen cancer patients
  • MicroRNA signatures linked with AML prognosis, cytogenetics
  • Stop-and-go oxaliplatin effective in elderly colon cancer patients
  • In vitro fertilization safe in women treated for endometrial carcinoma
  • High-dose methotrexate effective treatment for primary CNS lymphoma
  • Docetaxel every three weeks best for certain metastatic prostate cancers
  • Chewing gum after cystectomy stimulates return of bowel motility
  • Surgeon factors affect receipt of radiotherapy for breast cancer
  • Multimodal treatment may help in invasive bladder cancer
    •

    Leave a Reply

    « G-CSF induces bone loss, promotes bone tumor growth in mice
    GHRH antagonists enhance docetaxel effects on breast cancer »